- •Patients with moyamoya disease have renal artery lesions and renovascular hypertension.
- •Postoperative complications are more likely to occur in moyamoya disease patients with hypertension.
- •Stages of hypertension and whether or not taking antihypertensive drugs are associated with clinical outcomes.
Our study aimed to compare the disparity of patients with moyamoya disease (MMD) between hypertension group and non-hypertension group. And we attempt to explore the risk factors for MMD with hypertension.
We retrospectively analyze 542 adult patients with moyamoya disease admitted to our hospital from 2009 to 2016. In view of inclusion criteria, we divided patients with moyamoya disease into two groups (hypertension group and non-hypertension group) and summarized their clinical characteristics. Furthermore, we explore the risk factors for unfavorable outcomes in hypertension group.
Of 542 adult patients with moyamoya disease, we identified 156 patients (28.8%) with hypertension and 386 patients (71.2%) without hypertension. During follow-up, we hold the views that the prognosis of non-hypertension group was obviously better than hypertension group (P = 0.005) and the complications were prone to occurring to patients with hypertension (P = 0.037). In the multivariate analysis, severe hypertension (OR, 2.746; 95% CI, 1.096–6.822; P = 0.031) and no anti-hypertensive medication (OR, 0.342; 95% CI, 0.131–1.895; P = 0.029) were the independent predictors for postoperative unfavorable outcomes. The common surgical modalities of moyamoya disease (direct and indirect bypass) had no significant difference in future unfavorable outcomes prevention in adult MMD patients with hypertension.
We suggested severe hypertension and no anti-hypertensive medication as the independent risk factors for unfavorable clinical outcomes in adult MMD with hypertension.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Clinical Neuroscience
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Cerebrovascular, “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain.Arch Neurol. 1969; 20: 288-299
- Moyamoya disease complicated with renal artery stenosis and nephrotic syndrome: reversal of nephrotic syndrome after nephrectomy.J Pediatr. 2001; 138: 418-420
- Renal artery stenosis in moyamoya syndrome.J Cardiovasc Surg (Torino). 1994; 35: 441-443
- Progress in moyamoya disease.Neurosurg Rev. 2018;
- Renal artery lesions in patients with moyamoya disease: angiographic findings.Stroke. 2000; 31: 733-737
- Moyamoya disease: epidemiology, clinical features, and diagnosis.J Stroke. 2016; 18: 2-11
- 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Circulation. 2018; 138: e426-e483
- Novel mechanisms contributing to cerebral vascular dysfunction during chronic hypertension.Curr Hypertens Rep. 2001; 3: 517-523
- Hypertension, cerebral vascular changes and stroke in Ghana: cerebral atherosclerosis and stroke.East Afr Med J. 1989; 66: 468-475
- Severe hypertension: definition and patients profiles.Rev Prat. 2013; 63: 672-676
- Impact of severe hypertension in acute heart failure in Brazzaville (Congo).Med Sante Trop. 2012; 22: 98-99
- The risk of cardiovascular events in primary care patients following an episode of severe hypertension.J Clin Hypertens (Greenwich). 2009; 11: 175-182
- Sex differences in Hypertension: Where we have been and where we are going.Am J Hypertens. 2018;
- Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey.Stroke. 2008; 39: 42-47
- Novel epidemiological features of moyamoya disease.J Neurol Neurosurg Psychiatry. 2008; 79: 900-904
- Epidemiological features of moyamoya disease in Japan.Neurol Med Chir (Tokyo). 2012; 52: 295-298
- Epidemiological survey of moyamoya disease in Korea.Clin Neurol Neurosurg. 1997; 99: S6-S10
- Epidemiological and clinical features of Moyamoya disease in Nanjing.China. Clin Neurol Neurosurg. 2010; 112: 199-203
- Moyamoya disease: treatment and outcomes.J Stroke. 2016; 18: 21-30
- Endovascular treatment of symptomatic moyamoya.Neurosurg Rev. 2014; 37: 579-583
Davis KE. Expenditures for Hypertension among Adults Age 18 and Older, 2010: Estimates for the U.S. Civilian Noninstitutionalized Population. Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville (MD); 2001.
- Prevalence of and trends in diabetes among adults in the United States, 1988–2012.JAMA. 2015; 314: 1021-1029
- Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011–2012.NCHS Data Brief. 2013; : 1-8
- Prevalence and predictors of co-occurring diabetes and hypertension in community-dwelling older adults.Geriatr Gerontol Int. 2018; 18: 1356-1360
- Recruitment of older adults with type 2 diabetes into a community-based exercise and nutrition randomised controlled trial.Trials. 2016; 17: 467
- Impact of a brief intervention on self-regulation, self-efficacy and physical activity in older adults with type 2 diabetes.J Behav Med. 2015; 38: 886-898
- Diabetes, hypertension, obesity, and long-term risk of renal disease mortality: racial and socioeconomic differences.J Diabetes Investig. 2017; 8: 590-599
- Risk factors for and outcomes of postoperative complications in adult patients with moyamoya disease.J Neurosurg. 2018; 1–12
Published online: April 02, 2020
Accepted: December 1, 2019
Received: August 31, 2019
© 2019 Published by Elsevier Ltd.